BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12404104)

  • 21. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
    Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk.
    Bratt O; Borg A; Kristoffersson U; Lundgren R; Zhang QX; Olsson H
    Br J Cancer; 1999 Oct; 81(4):672-6. PubMed ID: 10574254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer.
    Kim SC; Ju W; Mahavni V; Geisler JP; Buller RE
    Int J Gynecol Cancer; 2006; 16 Suppl 1():190-4. PubMed ID: 16515589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Lynch HT; Neuhausen SL; Ghadirian P; Isaacs C; Weber B; Kim-Sing C; Foulkes WD; Gershoni-Baruch R; Ainsworth P; Friedman E; Daly M; Garber JE; Karlan B; Olopade OI; Tung N; Saal HM; Eisen A; Osborne M; Olsson H; Gilchrist D; Sun P; Narod SA
    Cancer Causes Control; 2005 Aug; 16(6):667-74. PubMed ID: 16049805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
    J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
    Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
    Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma.
    Li AJ; Baldwin RL; Karlan BY
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3667-73. PubMed ID: 14506156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.
    Rebbeck TR; Wang Y; Kantoff PW; Krithivas K; Neuhausen SL; Godwin AK; Daly MB; Narod SA; Brunet JS; Vesprini D; Garber JE; Lynch HT; Weber BL; Brown M
    Cancer Res; 2001 Jul; 61(14):5420-4. PubMed ID: 11454686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat.
    Rebbeck TR; Kantoff PW; Krithivas K; Neuhausen S; Blackwood MA; Godwin AK; Daly MB; Narod SA; Garber JE; Lynch HT; Weber BL; Brown M
    Am J Hum Genet; 1999 May; 64(5):1371-7. PubMed ID: 10205268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers.
    Sade RB; Chetrit A; Figer A; Papa MZ; Flex D; Rizel S; Friedman E
    Eur J Cancer; 2006 Mar; 42(5):650-5. PubMed ID: 16464572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
    King MC; Marks JH; Mandell JB;
    Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
    Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.
    Colilla S; Kantoff PW; Neuhausen SL; Godwin AK; Daly MB; Narod SA; Garber JE; Lynch HT; Brown M; Weber BL; Rebbeck TR
    Carcinogenesis; 2006 Mar; 27(3):599-605. PubMed ID: 16244359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population.
    Giguère Y; Dewailly E; Brisson J; Ayotte P; Laflamme N; Demers A; Forest VI; Dodin S; Robert J; Rousseau F
    Cancer Res; 2001 Aug; 61(15):5869-74. PubMed ID: 11479228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of the I1307K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers.
    Gershoni-Baruch R; Patael Y; Dagan ; Figer A; Kasinetz L; Kadouri E; Bruchim Bar Sade R; Friedman E
    Br J Cancer; 2000 Jul; 83(2):153-5. PubMed ID: 10901363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
    Hughes DJ; Ginolhac SM; Coupier I; Barjhoux L; Gaborieau V; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Sobol H; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Yannoukakos D; Mazoyer S; Lynch HT; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
    Int J Cancer; 2005 Nov; 117(2):230-3. PubMed ID: 15900600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Lynch HT; Klijn J; Ghadirian P; Neuhausen SL; Kim-Sing C; Foulkes WD; Moller P; Isaacs C; Domchek S; Randall S; Offit K; Tung N; Ainsworth P; Gershoni-Baruch R; Eisen A; Daly M; Karlan B; Saal HM; Couch F; Pasini B; Wagner T; Friedman E; Rennert G; Eng C; Weitzel J; Sun P; Narod SA; ; Garber J; Osborne M; Fishman D; McLennan J; McKinnon W; Merajver S; Olsson H; Provencher D; Pasche B; Evans G; Meschino WS; Lemire E; Chudley A; Rayson D; Bellati C
    Breast Cancer Res Treat; 2007 Oct; 105(2):221-8. PubMed ID: 17245541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
    Marroni F; Aretini P; D'Andrea E; Caligo MA; Cortesi L; Viel A; Ricevuto E; Montagna M; Cipollini G; Federico M; Santarosa M; Marchetti P; Bailey-Wilson JE; Bevilacqua G; Parmigiani G; Presciuttini S
    Eur J Hum Genet; 2004 Nov; 12(11):899-906. PubMed ID: 15340362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A CAG repeat polymorphism in the androgen receptor gene is associated with reduced bone mass and increased risk of osteoporotic fractures.
    Langdahl BL; Stenkjaer L; Carstens M; Tofteng CL; Eriksen EF
    Calcif Tissue Int; 2003 Sep; 73(3):237-43. PubMed ID: 14667136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.